Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer

Based upon results of the KEYNOTE-522 trial and following approval by regulatory authorities, the addition of pembrolizumab to chemotherapy is now the standard-of-care for the treatment of early triple-negative breast cancer (eTNBC) (Clinical stage II-III). Pembrolizumab is a programmed cell death p...

Descripción completa

Detalles Bibliográficos
Autores principales: Marhold, Maximilian, Udovica, Simon, Halstead, Anna, Hirdler, Mona, Ferner, Muna, Wimmer, Kerstin, Bago-Horvath, Zsuzsanna, Exner, Ruth, Fitzal, Florian, Strasser-Weippl, Kathrin, Robinson, Tim, Bartsch, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653620/
https://www.ncbi.nlm.nih.gov/pubmed/38025838
http://dx.doi.org/10.1080/2162402X.2023.2275846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653620/
https://www.ncbi.nlm.nih.gov/pubmed/38025838
http://dx.doi.org/10.1080/2162402X.2023.2275846

Ejemplares similares